Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 5/20 | 0.55 |
| ▸ | DRD2 | P14416 | 3/20 | 0.55 |
| ▸ | DRD3 | P35462 | 3/20 | 0.55 |
| ▸ | DRD1 | P21728 | 2/20 | 0.55 |
| ▸ | HTR2A | P28223 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.51 |
| ▸ | KDM1A | O60341 | 1/20 | 0.51 |
| ▸ | DRD5 | P21918 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6292618 | 0.93 | TMEM97 (0.51) | HTR1ADRD2DRD3DRD1HTR2A | |
| SCHEMBL2024052 | 0.89 | HTR1A (0.56) | HTR1ADRD2DRD3DRD1HTR2A | |
| SCHEMBL9557902 | 0.87 | HTR1A (0.58) | HTR1ADRD2DRD3DRD1HTR2A | |
| SCHEMBL7432164 | 0.84 | MEN1 (0.54) | MEN1KMT2AKDM4E | |
| SCHEMBL26108581 | 0.82 | HTR1A (0.65) | HTR1ADRD2DRD3DRD1HTR2A | |
| SCHEMBL26492991 | 0.82 | HTR1A (0.65) | HTR1ADRD2DRD3DRD1HTR2A | |
| SCHEMBL23252522 | 0.81 | HTR1A (0.53) | HTR1ADRD2DRD3DRD1HTR2A | |
| SCHEMBL6399783 | 0.81 | MEN1 (0.58) | HTR1ADRD2DRD3DRD1HTR2A | |
| SCHEMBL7488861 | 0.81 | MEN1 (0.56) | HTR1ADRD2DRD3DRD1HTR2A | |
| SCHEMBL1307809 | 0.81 | POLB (0.53) | HTR1ADRD2DRD3DRD1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040235930-A1 | Indole derivatives and their use for the treatment of osteoporosis amongst other applications | FARINA CARLO (IT) | 2004-11-25 | — | — | US | claimed |
| US-6787550-B1 | 4-(5,6-DICHLORO-1H-INDOL-2-YL)-3-ETHOXY-N-(2,2,6,6 -TETRAMETHYLTETRAMETHYLPIPERIDIN-4-YL)-BENZAMIDE | NIKEM RESEARCH S.R.L. (IT) | 2004-09-07 | — | — | US | claimed |
| CN-1370159-A | Indole derivatives and their use for treatment of osteoporosis amongst other applications | SMITHKLINE BEECHAM SPA (IT) | 2002-09-18 | — | — | CN | claimed |
| EP-1212317-A1 | INDOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF OSTEOPOROSIS AMONGST OTHER APPLICATIONS | GlaxoSmithKline S.p.A. (IT) | 2002-06-12 | — | — | EP | claimed |
| WO-2001002388-A1 | INDOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF OSTEOPOROSIS AMONGST OTHER APPLICATIONS | GLAXOSMITHKLINE S.P.A. (IT) | 2001-01-11 | — | — | WO | claimed |
| US-7220769-B2 | Azolylbenzamides and analogues and their use for treating osteoporosis | NIKEM RESEARCH S.R.L. (IT) | 2007-05-22 | — | — | US | disclosed |
| US-6903117-B2 | Indole derivatives for the treatment of osteoporosis | NIKEM RESEARCH S.R.L. (IT) | 2005-06-07 | — | — | US | disclosed |
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | 3-V BIOSCIENCES, INC. | 2005-02-17 | — | — | US | disclosed |
| CN-1179960-C | Indole derivatives and their use in the treatment of osteoporosis and other uses | ʷ��˿�������ȳ�ķ�ɷݹ�˾ | 2004-12-15 | — | — | CN | disclosed |
| US-20040235930-A1 | Indole derivatives and their use for the treatment of osteoporosis amongst other applications | FARINA CARLO (IT) | 2004-11-25 | — | — | US | disclosed |
| EP-1212317-B1 | INDOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF OSTEOPOROSIS AMONGST OTHER APPLICATIONS | NIKEM RESEARCH SRL (IT) | 2004-09-15 | — | — | EP | disclosed |
| US-6787550-B1 | 4-(5,6-DICHLORO-1H-INDOL-2-YL)-3-ETHOXY-N-(2,2,6,6 -TETRAMETHYLTETRAMETHYLPIPERIDIN-4-YL)-BENZAMIDE | NIKEM RESEARCH S.R.L. (IT) | 2004-09-07 | — | — | US | disclosed |
| US-5981525-A | FOR THERAPY OR PROPHYLAXIS OF OSTEOPOROSIS,TUMOURS, ULCERS, AUTOIMMUNE DISEASES, LIPIDEMIC DISORDERS, HYPERCHOLESTEROLEMIC AND ATHEROSCLEROTIC DISEASES, AIDS ALZHEIMER'S DISEASE | SMITHKLINE BEECHAM CORPORATION (US) | 1999-11-09 | — | — | US | disclosed |
| EP-0914321-A1 | INDOLE DERIVATIVES FOR THE TREATMENT OF OSTEOPOROSIS | Smithkline Beecham S.p.A. (IT) | 1999-05-12 | — | — | EP | disclosed |
| CN-1177957-A | Indole derivatives for the treatment of osteoporosis | SMITHKLINE BEECHAM SPA (IT) | 1998-04-01 | — | — | CN | disclosed |
| WO-1998001443-A1 | INDOLE DERIVATIVES FOR THE TREATMENT OF OSTEOPOROSIS | SMITHKLINE BEECHAM S.P.A. (IT) | 1998-01-15 | — | — | WO | disclosed |
| WO-1996021644-A1 | INDOLE DERIVATIVES USEFUL IN THE TREATMENT OF OSTEOPOROSIS | SMITHKLINE BEECHAM S.P.A. (IT) | 1996-07-18 | — | — | WO | disclosed |
| US-5215967-A | AMINOACID DERIVATIVES INHIBITING RENIN | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1993-06-01 | — | — | US | disclosed |
| US-4895846-A | CARDIOVASCULAR DISORDERS | BRISTOL-MYERS COMPANY (US) | 1990-01-23 | — | — | US | disclosed |
| US-4755512-A | Pharmaceutically useful dihydropyridinyldicarboxylate amides and esters incorporating arylpiperazinylalkyl moities | BRISTOL-MYERS COMPANY (US) | 1988-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | NR0B2, NR0B1, NCOR1 | HTR1A 3880/4885DRD2 3803/4885DRD3 3697/4885 |
| US-20040235930-A1 | Indole derivatives and their use for the treatment of osteoporosis amongst other applications | MALT1, SOST, NFATC1 | HTR1A 291/4885DRD2 1893/4885DRD3 1345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.